What is Fairtility?
Fairtility is at the forefront of revolutionizing the in vitro fertilization (IVF) process through the application of transparent artificial intelligence. Their flagship product, CHLOE (Cultivating Human Life through Optimal Embryos), is a proprietary embryo grading platform designed to offer clinicians and patients unparalleled visibility into the critical clinical and laboratory parameters that influence IVF success rates. By providing this detailed insight, Fairtility aims to improve treatment outcomes and streamline the patient journey. The company's strategic vision extends beyond embryo grading, with plans to broaden CHLOE's capabilities across the entire IVF spectrum, from initial infertility cause assessment to optimizing embryo transfer.
How much funding has Fairtility raised?
Fairtility has raised a total of $18.5M across 2 funding rounds:
Angel/Seed
$3.5M
Series A
$15M
Angel/Seed (2020): $3.5M, investors not publicly disclosed
Series A (2022): $15M led by Nacre Capital and Gurnet Point Capital
Key Investors in Fairtility
Nacre Capital
Nacre Capital is a venture capital firm specializing in building and scaling disruptive startups that utilize deep technologies. They provide comprehensive support, including financial backing and business development, to help transform innovative ideas into market-leading companies.
Gurnet Point Capital
Gurnet Point Capital is a healthcare-focused investment fund that provides long-term capital and strategic support to entrepreneurs in life sciences and medical technologies. They invest across all stages of product development and commercialization.
What's next for Fairtility?
With the recent major strategic investment and a substantial total funding amount of $18.5M, Fairtility is poised for significant expansion and innovation. The company's focus on AI-driven decision support in the high-stakes field of IVF positions it for growth. Future developments will likely involve scaling the CHLOE platform, enhancing its AI algorithms, and potentially expanding its market reach globally. This capital will also support further research and development to integrate CHLOE across more stages of the IVF journey, solidifying Fairtility's role as a key player in fertility technology.
See full Fairtility company page
